Shanghai Fu Ren Solution competition for eight years failed to be named by the Bureau

Zhang Haijie told reporters that the controlling shareholder had no plans to restructure its assets. But according to reporter statistics, the controlling shareholder in the two-level market to reduce the "benefit" of our correspondent Zhang October 16, Shanghai Fu Ren announced that because of information disclosure violations by the Shanghai Securities and Regulatory Bureau issued the "Shanghai Securities Regulatory Bureau Administrative Supervision Measures decision book." It is noteworthy that the Shanghai Securities and Regulatory Bureau named Shanghai Fu Jen did not disclose in last year's annual report of the holding shareholder has made a commitment to avoid competition, the company's secretary Zhang Haijie told reporters that the company has not restructured plans and programs. It is noteworthy that the two-tier market, the controlling shareholder has benefited by reducing the shares of listed companies. The China Securities Regulatory Commission was named by the SEC to the Shanghai Supervision Bureau on October 14, 2013 to Shanghai Fu Jen Industrial (Group) Co., Ltd. issued the "Shanghai Securities Regulatory Bureau Administrative Supervision Measures decision book", pointed out that the company has the following problems. First of all, the company did not disclose in the 2012 annual report of the holding shareholder Fu Ren Pharmaceutical Group Co., Ltd. in 2005 to avoid competition commitments. In addition, in September 2012, the company's holding subsidiary Henan Fu Ren Tang Pharmaceutical Co., Ltd. received two government grants, respectively, 2.84 million yuan, 5 million yuan. However, the company has not disclosed the interim report on the above matters in a timely manner. Shanghai Securities and Regulatory Bureau is now asking the company to attach great importance to the above issues, not in line with the above provisions of the conduct of timely rectification. And before November 15, 2013, to the Shanghai Securities Regulatory Bureau to submit a written report. In eight years of competition, the issue was named by the Securities and Regulatory Bureau investors are more concerned about the Shanghai Fu Ren and the holding shareholder auxiliary Benevolence Pharmaceutical Group competition, outside speculation, in recent years, Shanghai Fu Jen performance is flat, the future holding shareholder Fu Ren Pharmaceutical group or have another injection of some of the assets may. In the process of promoting reorganization in 2005, Fu Ren Pharmaceutical group pledged to solve the problem of competition among the peers. It is understood that, in addition to holding Henan Fu Ren Tang Pharmaceutical Co., Ltd., auxiliary benevolence Pharmaceutical Group has: Henan Auxiliary Renhuai Qing Tang Pharmaceutical Co., Ltd., Kaifeng Pharmaceutical (Group) Co., Ltd., Kaifeng Port Pharmaceutical Co., Ltd., Henan Homologous Pharmaceutical Co., Ltd., Fu Jen Pharmaceutical Technology Development Co., Ltd., Fu Ren Pharmaceutical Group Pharmaceutical Co., Ltd., such as a number of wholly-owned, holding subsidiaries. Products covered by Chinese and Western medicine preparations, biochemical pharmaceuticals, bio-pharmaceutical, raw materials, such as drugs and many other categories. However, over the past eight years, this competition has not been resolved. In the face of a decline in corporate performance, there is speculation that controlling shareholders may be able to inject some of their assets into listed companies again. In this respect, Shanghai Fu Ren Dong Zhang Haijie to reporters that there is no specific plan and plans. Controlling shareholder's multiple reduction although Zhang Haijie told reporters that the controlling shareholder did not plan to restructure its assets, the controlling shareholder "benefited" from the listed companies. According to the reporter statistics, the second half of this year, the auxiliary benevolence group has repeatedly reduced the listed company shares, respectively: August 21, 2013, Fu Ren Group through the Shanghai Stock Exchange centralized trading system to reduce the shares of the company 2600 shares, reduce the average price of 14.94 yuan/share, August 26 reduce the company shares 7.19 million shares, reduce the average price of 13.74 yuan/share. The total amount of the reduced shares has reached 5% of the company's overall equity. This time the company benefited about 99 million yuan. Since then, the auxiliary benevolence group from September 2, 2013 to September 3, through the Shanghai Stock Exchange centralized trading system to reduce the company's shares over 1.28 million shares, reduce the average price of 13.77 yuan/shares, on September 3, 2013 through the Shanghai Stock Exchange bulk trading system holdings 7.59 million shares, Reduce the average price of 12.39 yuan/share, the total number of shares reduced to the company's overall share capital of 5%. This time, the company benefited nearly 110 million yuan. Fu Jen Group on September 10, 2013, through the Shanghai Stock Exchange centralized trading system to reduce the company's shares 268,400 shares, accounting for the company's total equity of 0.151%; On the same day, through the Shanghai Stock Exchange bulk trading system to reduce the company's shares 5.9 million shares, accounting for the company's total capital of 3.322%. The lowest price for the day is 13.59 yuan/share. This time, the company received about 83 million yuan in earnings. Less than one months of time, the auxiliary benevolence group through the two-level market to reduce the stock of Shanghai Fu Ren benefited nearly 300 million yuan, and Shanghai Fu Jen since 2006 attributable to the parent shareholder's net profit and only for the super 200 million yuan. According to the latest announcement of Shanghai Fu Ren, the controlling shareholder, Fu Ren Group, holds 48.1 million shares, accounting for 27.084% of total equity, and remains the largest shareholder of the company.